[go: up one dir, main page]

WO1998038988A1 - Utilisation de la pivagabine dans la preparation de compositions pharmaceutiques - Google Patents

Utilisation de la pivagabine dans la preparation de compositions pharmaceutiques Download PDF

Info

Publication number
WO1998038988A1
WO1998038988A1 PCT/EP1998/001279 EP9801279W WO9838988A1 WO 1998038988 A1 WO1998038988 A1 WO 1998038988A1 EP 9801279 W EP9801279 W EP 9801279W WO 9838988 A1 WO9838988 A1 WO 9838988A1
Authority
WO
WIPO (PCT)
Prior art keywords
pivagabin
depressive
pharmaceutical composition
administration
gaba
Prior art date
Application number
PCT/EP1998/001279
Other languages
English (en)
Inventor
Gaetano Esposito
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority to AU70317/98A priority Critical patent/AU7031798A/en
Priority to IL13135598A priority patent/IL131355A0/xx
Priority to JP53816898A priority patent/JP2001513800A/ja
Publication of WO1998038988A1 publication Critical patent/WO1998038988A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the pharmacotoxicological profile of pivagabin is as follows: - it is substantially free of toxic effects in vivo in the mouse and in the rat; in fact, LD 50 by intravenous route is of 1750 mg/kg in the mouse while no toxic effects were observed up to the dose of 1 g/kg by intraperitoneal route in the rat;
  • the pharmaceutical composition of this invention may contain other pharmacologically active ingredients whose simultaneous administration is useful.
  • the quantity of pivagabin in the pharmaceutical composition of this invention will be such that it ensures a level of administration of from 5 to 250 mg/kg/day. Preferably, of from 10 to 150 mg/kg/day. Even more preferably, of from 10 to 50 mg/kg/day.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention a pour objet l'utilisation de la pivagabine pour préparer une composition pharmaceutique pour traiter les formes d'anxiété dépressive.
PCT/EP1998/001279 1997-03-03 1998-02-25 Utilisation de la pivagabine dans la preparation de compositions pharmaceutiques WO1998038988A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU70317/98A AU7031798A (en) 1997-03-03 1998-02-25 Use of pivagabin to prepare pharmaceutical compositions
IL13135598A IL131355A0 (en) 1997-03-03 1998-02-25 Use of pivagabin to prepare pharmaceutical compositions
JP53816898A JP2001513800A (ja) 1997-03-03 1998-02-25 医薬組成物調製のためのピバガビンの使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT97MI000456A IT1290003B1 (it) 1997-03-03 1997-03-03 Uso di pivagabina per preparare composizioni farmaceutiche
ITMI97A000456 1997-03-03

Publications (1)

Publication Number Publication Date
WO1998038988A1 true WO1998038988A1 (fr) 1998-09-11

Family

ID=11376246

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001279 WO1998038988A1 (fr) 1997-03-03 1998-02-25 Utilisation de la pivagabine dans la preparation de compositions pharmaceutiques

Country Status (7)

Country Link
JP (1) JP2001513800A (fr)
AR (1) AR011907A1 (fr)
AU (1) AU7031798A (fr)
IL (1) IL131355A0 (fr)
IT (1) IT1290003B1 (fr)
WO (1) WO1998038988A1 (fr)
ZA (1) ZA981729B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040009A1 (fr) * 2000-11-20 2002-05-23 H. Lundbeck A/S Promoteurs de l'acide gamma-aminobutyrique (gaba) dans le traitement de maladies liees a une reduction l'activite neurosteroide
EP2101585A4 (fr) * 2006-11-30 2011-06-15 Cenerx Biopharma Inc Esters dialkylamino alkylés de la pivagabine utilisés comme médicaments dans le traitement des troubles du système nerveux central
US11021430B2 (en) * 2016-04-05 2021-06-01 Moresco Corporation Oxa acid compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1202402B (it) * 1977-06-01 1989-02-09 Galzigna Lauro Derivati idrofobici dell'acido 4-aminobutirrico

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1202402B (it) * 1977-06-01 1989-02-09 Galzigna Lauro Derivati idrofobici dell'acido 4-aminobutirrico

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIANCHI: "Pharmacokinetics and in-vitro effects of a 4-aminobutyric acid derivative with anticonvulsivant action", PHARMACOLOGY, vol. 27, 1983, pages 237 - 240, XP002050234 *
BITRAN: "Anxiolytic effects of 3alpha-hydroxy-5alpha-(beta)-pregnan-20-one: endogenous metabolites of progesterone thet are active at the GABA-A receptor", BRAIN RES., vol. 561, 1991, pages 157 - 161, XP002050235 *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; XP002050236 *
ESPOSITO ET AL.: "Pivagabine: a novel psychoactive drug", ARZNEIM. FORSCHUNG, vol. 47, no. 11a, November 1997 (1997-11-01), pages 1306 - 1309, XP002066031 *
GIGLIOTTI ET AL.: "Role of pivagabine in the treatment of climacteric syndrome", ARZNEIM. FORSCHUNG, vol. 47, no. 11a, November 1997 (1997-11-01), pages 1317 - 1321, XP002066029 *
MANANI: "Evaluation of effects of intravenous premedication by trazodone, droperidol, N-pivaloyl-GABA and diazepam", ANEST. REANIM., vol. 29, no. 4, 1988, pages 313 - 323 *
NEGRI: "Evaluation of the efficacy of pivagabine on insomnia associated with mood disorders", ARZNEIM. FORSCHUNG, vol. 47, no. 11a, November 1997 (1997-11-01), pages 1322 - 1325, XP002066030 *
SCARPAGNINI ET AL.: "Effects of pivagabine on psychophysical performance and behavioral response in experimental models of stress", ARZNEIM. FORSCHUNG, vol. 47, no. 11a, November 1997 (1997-11-01), pages 1310 - 1314, XP002066028 *
SIRTORI: "Preface", ARZNEIM. FORSCHUNG, vol. 47, no. 11a, November 1997 (1997-11-01), pages 1303 - 1305, XP002066032 *
TERRANOVA ET AL.: "Clinical evaluation of the efficacy of pivagabine in the treatment of mood and adjustment disorders", ARZNEIM. FORSCHUNG, vol. 47, no. 11A, November 1997 (1997-11-01), pages 1325 - 1328, XP002066027 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040009A1 (fr) * 2000-11-20 2002-05-23 H. Lundbeck A/S Promoteurs de l'acide gamma-aminobutyrique (gaba) dans le traitement de maladies liees a une reduction l'activite neurosteroide
AU2002223514B2 (en) * 2000-11-20 2006-11-30 H. Lundbeck A/S Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
CN1318027C (zh) * 2000-11-20 2007-05-30 H·隆德贝克有限公司 与神经甾体活性降低相关的疾病的治疗中的gaba增强剂
EP2101585A4 (fr) * 2006-11-30 2011-06-15 Cenerx Biopharma Inc Esters dialkylamino alkylés de la pivagabine utilisés comme médicaments dans le traitement des troubles du système nerveux central
US8080548B2 (en) 2006-11-30 2011-12-20 Cenerx Biopharma, Inc. Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
US11021430B2 (en) * 2016-04-05 2021-06-01 Moresco Corporation Oxa acid compound

Also Published As

Publication number Publication date
AU7031798A (en) 1998-09-22
IL131355A0 (en) 2001-01-28
IT1290003B1 (it) 1998-10-19
ITMI970456A1 (it) 1998-09-03
ZA981729B (en) 1998-08-28
AR011907A1 (es) 2000-09-13
JP2001513800A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
US8119619B2 (en) Pregnane steroids and their use in the treatment of CNS disorders
US6245757B1 (en) Use of progestins to treat ischemic event
CA2321728C (fr) Epiallopregnanolone utilise pour traiter les troubles du systeme nerveux central
US20090143435A1 (en) GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity
JPH11509844A5 (fr)
JPH11509844A (ja) プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
AU2002223514A1 (en) Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
US6592845B2 (en) Estrogens for treating ALS
JP2003510336A (ja) 虚血性損傷においてのエストロゲンのエナンチオマーを用いる細胞保護の方法
FR2757400A1 (fr) Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
HUP0301317A2 (hu) Neuroprotektív hatású 7-béta-hidroxiszteroidok alkalmazása gyógyszerkészítmények előállítására
WO1998038988A1 (fr) Utilisation de la pivagabine dans la preparation de compositions pharmaceutiques
WO2010135798A1 (fr) Utilisation de la télocinobufagine comme analgésique dans le traitement de douleurs aiguës et chroniques, composition pharmaceutique contenant de la télocinobufagine et utilisation de celle-ci
BR112020019538A2 (pt) Antagonistas gaba-a para tratar transtornos por abstinência de substância
EP1393727B1 (fr) Agent curatif pour myelopathies
HK1075010B (en) Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131355

Country of ref document: IL

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GW HU ID IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 111299

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV1999-3101

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1999/02121

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 1998 538168

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997007979

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019997007979

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1019997007979

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-3101

Country of ref document: CZ

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA